Browse by author
Lookup NU author(s): Professor Chris Day
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
BACKGROUND & AIMS: ASP9831 is a phosphodiesterase-4 inhibitor developed to treat nonalcoholic steatohepatitis (NASH); it showed potent anti-inflammatory and antifibrotic effects in preclinical studies. We evaluated the efficacy and safety of ASP9831 in patients with NASH.METHODS: In a phase 1 trial, we determined the optimal therapeutic window of ASP9831 in healthy volunteers and evaluated 2 doses (50 and 100 mg) in patients with NASH. Based on the positive outcomes of the phase 1 study, we performed a phase 2 trial to compare the biochemical effects of ASP9831 vs placebo. Patients with NASH were assigned randomly to groups given either 50 mg (n=33) or 100 mg (n=33) ASP9831 twice daily, or placebo (n=30), for 12 weeks. The primary end point was the mean percentage change, from baseline to the end of ASP9831 administration, in serum level of alanine aminotransferase (ALT); secondary outcomes included changes in aspartate aminotransferase (AST) levels, ratio of AST: ALT, and various biomarkers of NASH.RESULTS: After 12 weeks of administration, there was no significant change in mean serum levels of ALT (P=.42) or AST (P=.20) or other biomarkers in any group, and no significant differences were observed among groups. Most adverse events were mild; gastrointestinal disorders occurred more frequently in the ASP9831 groups than the placebo group.CONCLUSIONS: Despite a relevant mechanism of action, ASP9831 did not significantly alter the biochemical markers of NASH, compared with placebo, in a clinical trial. This highlights the difficulties of developing therapeutics for NASH and the need for more extensive preclinical testing of mechanisms of potential drug candidates. Clinicaltrialsregister. eu: 2005-001687-31; EudraCT numbers: 2007-002114-19.
Author(s): Ratziu V, Bedossa P, Francque SM, Larrey D, Aithal GP, Serfaty L, Voiculescu M, Preotescu L, Nevens F, De Ledinghen V, Kirchner GI, Trunecka P, Ryder SD, Day CP, Takeda J, Traudtner K
Publication type: Article
Publication status: Published
Journal: Clinical Gastroenterology and Hepatology
Year: 2014
Volume: 12
Issue: 10
Pages: 1724-1730.e5
Print publication date: 01/10/2014
Online publication date: 12/02/2014
ISSN (print): 1542-3565
ISSN (electronic): 1542-7714
Publisher: W.B. Saunders Co.
URL: http://dx.doi.org/10.1016/j.cgh.2014.01.040
DOI: 10.1016/j.cgh.2014.01.040
Altmetrics provided by Altmetric